{
    "clinical_study": {
        "@rank": "23306", 
        "arm_group": [
            {
                "arm_group_label": "Group A", 
                "arm_group_type": "Experimental", 
                "description": "16 healthy volunteers Days 1-7 = IDX719 150 mg once daily and Days 8-14 = IDX719 150 mg once daily + simeprevir 150 mg once daily"
            }, 
            {
                "arm_group_label": "Group B", 
                "arm_group_type": "Experimental", 
                "description": "16 Healthy Volunteers Days 1-7 = simeprevir 150 mg once daily  and Days 8-14 = IDX719 150 mg once daily  + simeprevir 150 mg once daily"
            }, 
            {
                "arm_group_label": "Group C", 
                "arm_group_type": "Experimental", 
                "description": "8 Healthy Volunteers Days 1-14 = IDX719 150 mg once daily"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the potential for a pharmacokinetic (PK) drug-drug\n      interaction between simeprevir and IDX719 and to assess the safety and tolerability when the\n      two drugs are administered alone and in combination for up to 14 days in healthy subjects."
        }, 
        "brief_title": "Study to Evaluate Drug-Drug Interaction Between IDX719 and Simeprevir in Healthy Subjects", 
        "completion_date": {
            "#text": "May 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Hepatitis C Infection", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis, Chronic", 
                "Hepatitis C", 
                "Hepatitis C, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Read and signed the written informed consent form (ICF) after the nature of the study\n             has been fully explained.\n\n          -  All subjects of childbearing potential must have agreed to use a double method of\n             birth control (one of which must be a barrier) from Screening through at least 90\n             days after the last dose of the study drug\n\n        Exclusion Criteria:\n\n          -  Pregnant or breastfeeding."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01813513", 
            "org_study_id": "IDX-06A-004"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Group A", 
                    "Group B", 
                    "Group C"
                ], 
                "description": "50 mg tablets X 3, once daily", 
                "intervention_name": "IDX719", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Group A", 
                    "Group B"
                ], 
                "description": "150 mg capsule X 1, once daily", 
                "intervention_name": "simeprevir", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "HCV", 
            "Hepatitis C Virus", 
            "Hepatitis C", 
            "antiviral drugs", 
            "liver"
        ], 
        "lastchanged_date": "March 26, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Neptune", 
                    "country": "United States", 
                    "state": "New Jersey", 
                    "zip": "07753"
                }
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase I, Randomized, Multiple-Dose Study to Evaluate the Pharmacokinetic Drug-Drug Interaction Between IDX719 and Simeprevir in Healthy Subjects", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "- Pharmacokinetic measures of plasma drug exposure (AUCss and Cmax) of IDX719 and simeprevir", 
            "measure": "Pharmacokinetic parameters", 
            "safety_issue": "No", 
            "time_frame": "28 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01813513"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "- Safety and tolerability of IDX719 and simeprevir, alone and in combination, using key safety parameters (adverse events, physical examinations, vital signs, ECGs and standard laboratory safety tests).", 
            "measure": "Safety and Tolerability", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 14 days"
        }, 
        "source": "Idenix Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Idenix Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}